cell-free tumour DNA

Overview

Cell-free tumour DNA, more commonly referred to as circulating tumor DNA (ctDNA), is the tumour-derived fraction of cell-free DNA found in body fluids, especially blood plasma and, in some settings, cerebrospinal fluid. It consists of short DNA fragments released from cancer cells through apoptosis, necrosis, and active secretion, and it carries somatic alterations such as point mutations, copy-number changes, structural variants, and DNA methylation patterns that reflect the genomic and epigenomic state of the tumour.

Clinically, ctDNA is a major liquid biopsy analyte because it can be sampled noninvasively and repeatedly over time. It is being investigated for detection of minimal residual disease, prognosis, treatment selection, monitoring of response, and early identification of resistance or tumour evolution. Its utility is particularly relevant in Cancers such as breast cancer, colorectal cancer, non-small cell lung cancer, prostate cancer, melanoma, bladder cancer, esophageal squamous cell carcinoma, and diffuse glioma, where tissue-free molecular profiling may complement or, in some contexts, substitute for tissue-based testing.

Recent Publications Summary

Recent publications on cell-free tumour DNA (ctDNA) continue to emphasize its role as a minimally invasive biomarker for cancer detection, molecular stratification, and treatment monitoring. In glioma, cerebrospinal fluid ctDNA analysis was highlighted as a potentially useful liquid biopsy approach to support molecular reclassification and serial monitoring, although the abstract notes that its use in clinical practice remains limited by technical challenges 42168657May. In gastrointestinal and bladder Cancers, review articles described ctDNA as particularly valuable for minimal residual disease detection, early molecular relapse, and response assessment, while noting that diagnostic sensitivity can still be moderate in some settings 41992238Apr41933678Apr. In melanoma, an international expert survey underscored ctDNA’s promise for tumor burden assessment and the need to define optimal clinical applications and implementation barriers 41932032Apr.

Several studies focused on ctDNA as a prognostic or predictive tool in treatment settings. In stage II/III HER2-positive or triple-negative breast cancer, ctDNA minimal residual disease assessment was proposed as an additional or potentially superior risk stratification method after neoadjuvant therapy 41805422Mar. In stage III colon cancer treated in a phase III adjuvant FOLFOX-based trial, a tissue-free, epigenomic ctDNA assay was evaluated for prognostic value and postoperative risk stratification 41616224Jan. In metastatic colorectal cancer, ctDNA dynamics were examined in patients receiving cetuximab-based induction and maintenance therapy, with the study designed to assess whether ctDNA changes could inform clinical outcomes 41671078Feb. In hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole, baseline and dynamic ctDNA were prospectively evaluated for prognostic and predictive value in the BioItaLEE trial 41587113Jan.

Alongside these clinical applications, multiple recent reports described new analytical platforms for ctDNA detection. A disposable CRISPR-Nanozyme electrochemical biosensor for breast cancer ctDNA achieved a detection limit of 860 aM with a linear range from 1 fM to 1 nM, using CRISPR/Cas12a recognition and nanozyme-based signal amplification 42024570Apr. Another electrochemiluminescent biosensor combined a covalent organic framework-confined CsPbBr3 nanocomposite with CRISPR/Cas12a-driven DNA walking, reporting a detection limit of 5.4 fM, a linear range from 10 fM to 10 nM, and good selectivity for single-base mismatches, including performance in diluted serum and clinical plasma samples 41707429Feb. Together, these studies reflect continued progress in both the clinical translation and technical refinement of ctDNA-based liquid biopsy approaches 42024570Apr41707429Feb.

What Changes, What Holds

1. ctDNA is moving from a general liquid-biopsy marker to a context-dependent tool with uneven clinical readiness
NEW DIRECTION Recent work does not change the core account of ctDNA as a noninvasive cancer biomarker, but it does narrow expectations about where it is already usable. In glioma and several solid-tumour settings, the emphasis is now on serial monitoring, molecular reclassification, and minimal residual disease, while the same reports stress technical limits and only moderate sensitivity in some contexts 42168657May41992238Apr. That leaves the baseline intact but more conditional in practice.

2. ctDNA is increasingly being positioned as a prognostic and predictive adjunct rather than a purely descriptive marker
REINFORCES These studies strengthen the baseline claim that ctDNA can inform prognosis, treatment selection, and resistance monitoring, because they extend those uses into post-neoadjuvant breast cancer, adjuvant colon cancer, metastatic colorectal cancer, and first-line advanced breast cancer 41805422Mar41616224Jan. The main change is not direction but confidence: ctDNA is being tested as a risk-stratification layer alongside standard therapy, though the summary still leaves open how much it outperforms existing clinical models.

3. New assay platforms are changing how ctDNA can be measured, not what ctDNA is for
METHOD The recent biosensor reports add technical refinement rather than a new biological role, showing continued movement toward more sensitive, selective, and potentially deployable detection methods for ctDNA 42024570Apr41707429Feb. That matters for clinical translation because assay performance remains a major bottleneck, but it does not alter the baseline understanding of ctDNA as a tumour-derived analyte used for liquid biopsy. The contribution is methodological: better detection chemistry, not a different clinical meaning.

Overview update candidates: the need to qualify ctDNA’s clinical utility by tumour type and technical sensitivity; the expanding use of ctDNA for MRD/prognostic stratification in treatment settings.